This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new small study has revealed the impact of obesity on muscle structure in patients having a form of heartfailure called heartfailure with a preservedejectionfraction (HFpEF).
A novel study co-authored by a heartfailure cardiologist demonstrates the effectiveness of a newly developed scoring system in identifying patients with HeartFailure with PreservedEjectionFraction (HFpEF).
A mouse study of heartfailure with preservedejectionfraction (HFpEF) found male-female differences at the cellular level. The findings could have implications for how HFpEF is treated in women compared to men.
In ambulatory women ages 63-99 years, higher amounts of usual daily light and moderate intensity activities were associated with lower risk of developing heartfailure with preservedejectionfraction independent of demographic and clinical factors associated with heartfailure risk.
In mice with heartfailure with preservedejectionfraction (HFpEF), increasing ketone supply to the heart allowed their hearts to utilize more ketones and produce more energy.
announced that the peer-reviewed Journal of the American College of Cardiology: HeartFailure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heartfailure using commonly accepted willingness-to-pay thresholds. “Our healthcare system.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: HeartFailure Reveals that Despite Significant Efforts to Improve Acute HeartFailure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Circulation: HeartFailure, Volume 16, Issue 11 , Page e010849, November 1, 2023. Mediation of the association between MMP-2 and HF was assessed by censoring participants who developed AF or coronary heartdisease before HF. 1.81]), incident HF with preservedejectionfraction (1.44 [95% CI, 1.07–1.94]),
ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heartfailure (HF).MethodsFrom Patients diagnosed with preservedejectionfraction (HFpEF) were treated with Vericiguat combined with “ARNI, BB, SGLT2i” therapy.
Introduction Heartfailure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. HF with preservedejectionfraction (HFpEF) was the most common phenotype and increased significantly compared with the first period (46.3% and 29.2%, p<0.001).
Recent data suggest that sodium-glucose contransporter-2 inhibitors (SGLT2i) may mitigate development of cardiac arrythmias in patients with heartfailure with preservedejectionfraction and patients with ischemic heartdisease [1].
BackgroundSystemic chronic inflammation plays a role in the pathophysiology of both heartfailure with preservedejectionfraction (HFpEF) and metabolic dysfunction‐associated fatty liver disease. The study population was subdivided into non‐HF, pre‐HFpEF, and HFpEF groups at baseline. 10 mg/L) and 5.0
Lowering the raised LA mean pressure is a major therapeutic goal in any severely symptomatic left heartdisease, whether it is valvular or myocardial disease. It is prudent to understand, that even in systolic LV failure; it is the raised LVEDP that causes the symptoms and marks the limits of exercise capacity.
24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.
Yakubu Bene-Alhasan, MD milla1cf Tue, 04/02/2024 - 12:14 April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heartfailure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heartfailure.
Finerenone reduced the composite of total first and recurrent heartfailure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preservedejectionfraction, according to an international clinical trial.
Finerenone and glycaemic status in patients with heartfailure with mildly reduced/preservedejectionfraction. CI, confidence interval; CV, cardiovascular; HF, heartfailure; HR, hazard ratio; RR, rate ratio.
Compared with those who spent most of their time in a single room, people with heartfailure with preservedejectionfraction (HFpEF) who were able to travel outside of their home without assistance were significantly less likely to be hospitalized or die within a year, according to a new study.
Background:SGLT2 inhibitors have demonstrated efficacy in reducing cardiovascular death and hospitalization and are recommended as first-line therapy for hear failure (HF) in adults due to acquired heartdiseases. We excluded articles related to acute decompensated HF and HF with preservedejectionfraction.
Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heartfailure that has had few therapeutic options.
There are significant data that show that if you have obesity, you have a high risk of developing coronary heartdisease, heartfailure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?
HCM is the most common genetic heartdisease worldwide and is estimated to affect 1 in 500 people. It causes the heart muscle to become stiff and thick, making it harder for the heart to pump blood properly and increasing the risk of sudden cardiac death. These data strongly support moving on to phase 3 development.”
Journal of the American Heart Association, Ahead of Print. BackgroundSparce data suggest higher mortality in heartfailure (HF) with left ventricular ejectionfraction (EF) >65% to 70%. We characterized EF distribution, characteristics, and outcomes in patients with HF and EF 50%.Methods
An international team of researchers has discovered a natural mechanism that protects the heart from heartfailure with preservedejectionfraction (HFpEF), a serious condition in need of effective treatment. Importantly, restoring the mechanism prevents the progression of the condition.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content